【抗体が効く】コロストラム(初乳)サプリ

2021/10/15(金) 22:22:23.32

Bovine Coronavirus Immune Milk Against COVID-19
https://www.frontiersin.org/articles/10.3389/fimmu.2021.637152/full

ウシ初乳中のBCoV(ウシコロナ)に対する抗体＝IgG(免疫グロブリンG)が
SARS-CoV-2のMタンパクやS2サブユニットに交差反応する

経口摂取により腸管等のリンパ組織でIgGが
免疫細胞のFc受容体に結合しシステミックな免疫反応を促進する

抗炎症作用も併せ持つ

【関連論文】
Effects of Bovine Immunoglobulins on Immune Function, Allergy, and Infection
https://www.frontiersin.org/articles/10.3389/fnut.2018.00052/full
https://www.frontiersin.org/files/Articles/387506/fnut-05-00052-HTML/image_m/fnut-05-00052-g002.jpg
https://www.frontiersin.org/files/Articles/387506/fnut-05-00052-HTML/image_m/fnut-05-00052-t004.jpg
作用機序・呼吸器感染症への有効性のエビデンス

Early Recovery of COVID-19 Patients by Using Immunoglobulins
Present in Cow Colostrum Food Supplement-A Clinical Study
https://www.jrmds.in/articles/early-recovery-of-covid19-patients-by-using-immunoglobulins-present-in-cow-colostrum-food-supplementa-clinical-study-68002.html
https://www.longdom.org/articles-images-2021/medical-dental-science-control-group-9-3-186-g004.png
COVID-19患者への投与で早期快復効果を示したランダム化比較試験

Augmented antiviral T cell immunity by oral administration of
IMM-124E in preclinical models and a phase I/IIa clinical trial:
A method for the prevention and treatment of COVID-19
https://onlinelibrary.wiley.com/doi/10.1002/ddr.21890
健康な被験者への投与でT細胞を活性化しSARS-CoV-2スパイクタンパクへの
曝露時にインターフェロンγ産生の増加効果を示した臨床試験

2022/01/21(金) 23:23:23.94

Broadly Neutralizing Bovine Antibodies:
Highly Effective New Tools against Evasive Pathogens?
https://www.mdpi.com/1999-4915/12/4/473/htm
> 2. The Long CDR H3 Is Generated Inefficiently in Humans
> 3. Ultralong CDR H3 Are Prevalent in the Cow Ab Repertoire
> 6. Long CDR H3 Structures Confer Broadly Neutralizing Anti-Viral Properties

>>43二番目論文と関連するがCDR(相補性決定領域)の長い抗体は
広域的な中和活性を持ちウイルスの変異にも適応しやすい
そのような抗体はヒトでは生成され難いがウシでは優勢

2022/01/25(火) 23:23:22.87

Bovine-derived antibodies and camelid-derived nanobodies as
biotherapeutic weapons against SARS-CoV-2 and its variants: A review article
https://www.sciencedirect.com/science/article/pii/S1743919122000103
>Multivalent nanobodies resist the mutations of the SARS-CoV-2 variant
>through two mechanisms: increased avidity for the ACE2 binding domain and
>identification of preserved epitopes that are not accessible to human antibodies [134].

>>76の構造的特徴によりウシ抗体は変異に適応しやすいが
nanobodyというラクダ抗体もまた変異に適応しやすい
ラクダの話は>>3にも